Last reviewed · How we verify
NCT07492953
Using Enhanced External Counterpulsation to Recover Cardiovascular Function for Patient of Chronic Diseases
NA trial testing enhanced external counterpulsation in Long COVID Symptoms in 10 participants. Completed in 24 June 2024.
24 June 2024
Quick facts
| Lead sponsor | National Defense Medical Center, Taiwan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 25 December 2023 |
| Primary completion | 24 June 2024 |
| Estimated completion | 24 June 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- enhanced external counterpulsation
Conditions studied
- Long COVID Symptoms — all drugs for Long COVID Symptoms →
Sponsor
National Defense Medical Center, Taiwan
Who can join
Eligibility, any sex, with Long COVID Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn whether enhanced external counterpulsation (EECP) therapy can improve cardiopulmonary function and symptoms in adults with long COVID. It will also evaluate the safety and feasibility of two different EECP treatment schedules. The main questions it aims to answer are: * Does EECP therapy improve functional exercise capacity and cardiopulmonary performance in patients with long COVID? * Do different EECP treatment schedules (standard vs. accelerated sessions) lead to different improvements in symptoms, quality of life, and physiological outcomes? * What side effects or medical problems occur during EECP therapy? Researchers will compare two EECP treatment schedules to determine whether a shorter, accelerated program provides similar benefits to the standard schedule. Participants will: * Receive EECP therapy either 1 hour per day (5 days per week for 7 weeks) or 2 hours per day (5 days per week for about 4 weeks), both totaling 35 hours of treatment * Visit the cardiopulmonary rehabilitation clinic regularly for supervised treatment sessions * Complete physical performance tests (such as the Six-Minute Walk Test and cardiopulmonary exercise testing) * Have blood pressure and heart rate measured * Complete questionnaires about symptoms, physical function, sleep quality, and quality of life
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07492953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of enhanced external counterpulsation
Trials testing the same drug.
- NCT06711003 — Effectiveness of Enhanced External Counterpulsation for Post-acute Stroke Patients · NA · recruiting
Other recruiting trials for Long COVID Symptoms
Currently open trials in the same condition.
- NCT07417176 — Persistent COVID-19 Registry in Navarre. · recruiting
Other National Defense Medical Center, Taiwan trials
Trials by the same sponsor.
- NCT07373002 — Development and Evaluation of an Intelligent Parent-Infant Connection-Based Intervention to Strengthen Family Resilience · NA · not yet recruiting
- NCT07488052 — Home-based Outpatient Multicenter Evaluation Using Electrocardiogram (HOME-ECG) · recruiting
- NCT07307729 — AI-Enabled ECG Stratification and Timing of Potassium-Lowering Therapy in Patients With Hyperkalemia: A Target Trial Emu · NA · not yet recruiting
- NCT07217236 — Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG · NA · recruiting
- NCT06887699 — The Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value- · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07492953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Defense Medical Center, Taiwan
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07492953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing